Delivering online education is a skill and an art that we have perfected by experience, working with hundreds of renowned faculty members and many of the world’s leading medical societies.
touchIMMUNOLOGY is proud to be at the forefront of on-demand and virtual formats, pushing the boundaries for online medical education.
- Learn more from touchIMMUNOLOGY with CME-accredited and independent learning activities
- Watch highlights and coverage from leading international immunology congresses
- Focused education on key topics in immunology, developed in collaboration with pharma
- Read the latest articles from our peer-reviewed therapy journals and unique expert insights developed for touchIMMUNOLOGY
About Touch Medical Media Group Holdings Ltd
Touch Medical Media Group Holdings Ltd is a non-trading holding Company which includes the following wholly owned subsidiary companies within the group; Touch Medical Communications Ltd, Touch Independent Medical Education Ltd & Touch Medical Media Services Ltd.
CME and Education is developed by Touch Independent Medical Education Ltd for touchIMMUNOLOGY.
Learning Zone activities are developed by Touch Medical Communications Ltd for touchIMMUNOLOGY and sponsored by the pharmaceutical industry.
Meet our Experts
Peter C Taylor
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
Peter C Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a Fellow of St. Peter’s College. He is Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for research on pathogenesis of arthritis. Professor Taylor has specialist clinical interests in inflammatory arthritis. He has over 25 years’ experience in clinical trial design in studies of biologic and small molecular therapies in rheumatoid arthritis and ankylosing spondylitis. In experimental medicine studies, Professor Taylor employs targeted therapies as probes of pathogenesis to investigate the in vivo biology of the target in the pathobiology of the disease phenotype under investigation.
Expert Faculty - Rheumatology
Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK
Dr Elena Nikiphorou is a Consultant Rheumatologist and an Honorary Senior Lecturer at Kings College London. She completed her MBBS at University College London, also obtaining a first-class honours for her Intercalated BSc in physiology, a British Pharmacological Society Award and a Wellcome Trust Vacation Scholarship for her BSc Research. She has been the recipient of multiple awards, bursaries and competitive roles, including the Richard Kovacs prize by the Royal Society of Medicine in 2014, which supported a fellowship in Chicago and the Doris Hillier Award by the British Medical Association in 2018, to support her work on multimorbidity in rheumatoid arthritis and the development of management algorithms according to individual need. with a clinical/academic interest in inflammatory arthritis, rheumatoid arthritis and spondyloarthritis. She has expertise in all aspects of general rheumatology, including connective tissue and metabolic bone disease; crystal (e.g., gout) and reactive arthritis.
Expert Faculty - Rheumatology
Université de Paris, Hôpital Cochin, Service de Rhumatologie, Paris, France
Jérôme Avouac is a senior rheumatologist at Cochin Hospital and Professor at the University of Paris. He is responsible for a sector of day hospitalisation in the Rheumatology department, whose recruitment is mainly composed of patients with chronic inflammatory rheumatic disorders. He established a standardized systematic follow-up of joint involvement and systemic complications of rheumatoid arthritis and other inflammatory rheumatic diseases. Based on this standardized follow-up and clinical studies, he is developing medical approaches of personalized medicine for rheumatoid arthritis. Within the “Pathogenesis And Innovative Therapies In Chronic Fibro-Inflammatory Diseases” team at the Cochin Institute (INSERM U1016 UMR8104), Prof. Avouac leads innovative projects regarding the vascular aspects of inflammatory rheumatic disorders, especially rheumatoid arthritis. He also participates in the preclinical evaluation of anti-fibrotic treatments thanks to a platform of complementary animal models with dermal, pulmonary and vascular fibrosis.
Expert Faculty - Dermatology
Dermatology Centre, Barnes Building, Salford Royal NHS Foundation Trust, Manchester, UK
Chris Griffiths qualified in Medicine from St Thomas’ Hospital Medical School, London, and trained in Dermatology at St Mary’s Hospital, London and the University of Michigan, USA. He was appointed to the Foundation Chair in Dermatology at the University of Manchester in 1994, and founded the Manchester Dermatopharmacology Unit and the Manchester Psoriasis Service in 1994. In 2015 he received the Sir Archibald Gray Medal, for outstanding service to British Dermatology, and in 2019, the British Society for Investigative Dermatology (BSID) Medal for contributions to research. In 2018 Chris was awarded Pro Meritis of the European Dermatology Forum and was appointed OBE for services to dermatology. He is an NIHR Emeritus Senior Investigator and a Fellow of the Academy of Medical Sciences. Professor Griffiths has 680 PubMed cited articles, and is Editor-in-Chief of Rook’s Textbook of Dermatology. He has a career-long interest in all aspects of psoriasis and is credited with helping to develop the concept that psoriasis is an immune-mediated disease.
Expert Faculty - Dermatology
Genetic Skin Disease Group, St John's Institute of Dermatology, King's College London, London, UK
Dr Su Lwin is a dermatology registrar and an honorary research fellow at St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospitals and King’s College London. Dr Lwin graduated from Guy’s, King’s and St Thomas’ School of Medicine in 2008 with an MBBS and a BSc (Hons) in neuroscience and basic medical sciences. In 2013, she joined St John’s Institute of Dermatology, initially as a clinical fellow, and subsequently in 2014 as a clinical research fellow in Professor John McGrath’s Genetic Skin Disease Group. For her PhD, Dr Lwin pioneered the first human trial of fibroblast gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Dr Lwin’s research focus includes the development and clinical application of somatic gene and cell therapy for individuals with EB and other genetic skin diseases, both at pre-clinical and clinical trial stages.
Expert Faculty - Dermatology
Centro Hospitalar, Universitário do Porto, Portugal
Tiago Torres is Professor of Dermatology at the Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal. He received his medical degree from the Faculty of Medicine, University of Porto, completed a residency program in Dermatology and Venereology at Centro Hospitalar Universitário do Porto (CHUP), and finished his PhD thesis in 2014 studying the role of psoriasis-associated systemic inflammation in atherosclerosis. Currently, he is the Head of the Immuno-dermatology Unit (psoriasis, atopic dermatitis and auto-immune diseases) and Clinical Trials Unit of the Department of Dermatology of CHUP. Tiago Torres is an Associate Editor for several journal publications and has published many articles on psoriasis and atopic dermatitis. His main research topics in dermatology are immune-dermatology, immunology and immunopharmacology of psoriasis and atopic dermatitis.
Expert Faculty - Dermatology
University of Rzeszow, Rzeszów, Poland
Adam Reich is Head and a full-time Professor at the Department of Dermatology, University of Rzeszow, Rzeszów, Poland. He is also a Secretary General of the Polish Dermatological Society and Chair of the Youth Forum of the Polish Dermatological Society. Dr Reich studied his PhD from 2003–2006 at the University of Medicine, Wroclaw, Poland. He is a member of the European Society for Dermatology and Psychiatry, European Society of Dermatological Research, European Academy of Dermatology and Venereology, International Forum for the Study of Itch, and the International Society of Dermatology. His is the author and co-author of 94 original research articles, 67 reviews and 47 case reports. He also awarded with Prof. Zdzisław Ruszczak Award for the scientific activity in psoriasis. Dr Reich’s research interests include psoriasis, psycho dermatology, itch, autoimmune connective tissue diseases and dermato-oncology.
Expert Faculty - Neurology
Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
Dr Sarosh R Irani is the head of the Oxford Autoimmune Neurology Group, and a consultant neurologist and clinician-scientist with experience in the field of autoantibody-mediated diseases of the nervous system, in particular the central nervous system. He runs a dedicated clinic for patients with these disorders, with a neuropsychiatrist and an encephalitis nurse. In parallel, he runs a research group of clinicians and scientists to learn more about the origins and treatments of these diseases. So far, their work has discovered new autoantibodies, such as those which target LGI1 and CASPR2; shown that autoantibody specificities can have a remarkably close relationship with the patient phenotype; and they have studied the cellular and humoral human immunology to understand the basis of these diseases. They are using these foundations to understand the breaks in immune tolerance and developing methods to rapidly generate patient-derived monoclonal antibodies to precisely explore the neuroscience mechanisms by which the antibodies cause disease.
Expert Faculty - Oncology/ Immunotherapy
Eva Monoz Couselo
Vall d’Hebron Hospital, Barcelona, Spain
Dr Muñoz obtained her degree in medicine and surgery from the University of Barcelona in 2005, and completed her residency in medical oncology at the Vall d’Hebrón Hospital in 2006–10. She was awarded the title of Doctor in Medical Oncology by the Autonomous University of Barcelona (2011). Dr Muñoz is a specialist in melanoma and other skin tumours, and part of the team of breast cancer and skin tumours is at the Medical Oncology Service of the Vall d’Hebron Hospital in Barcelona. In this centre, she is a principal investigator and co-investigator of multiple clinical trials. Dr Muñoz has authored/co-authored several publications, most notably in the fields of breast and melanoma tumours. She is a member of the Spanish Society of Medical Oncology and the Cooperative Groups EORTC, ESMO, SOLTI and GEM.
Expert Faculty - Diabetes/ Immunology
Yale School of Medicine, New Haven, CT, US
Kevan Herold, M.D., is Professor of Immunology and Internal Medicine, Endocrinology and Professor of Human and Translational Immunology at Yale University. Dr Herold graduated from Pennsylvania State University and Jefferson Medical College. He completed his residency at Temple University. His extensive career includes a Fellowship at the University of Chicago, Staff Scientist at Hagedeforn Laboratory in Denmark, and Scientific Director of the Juvenile Diabetes Research Foundation. Dr Herold has experience in conducting clinical trials with mechanistic studies to test new therapies and hypotheses to understand the basis for success or failures of responses. In addition, Dr Herold is interested in integrating approaches that would improve beta cell function or even regenerate beta cells that have been destroyed by the immune mechanisms that lead to the disease.
Expert Faculty - Rheumatology
Division of Rheumatology, Northwell Health, and Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
Dr Richard Furie is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s systemic lupus erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. He has served on many committees of the American College of Rheumatology and was named a Master of the College in 2018.
Expert Faculty - Gastroenterology
Gil Y Melmed
Inflammatory Bowel and Immunobiology Research Institute, and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Gil Y Melmed, MD, MS, is the Co-Director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, CA, USA. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and master of science in clinical research from the University of California, School of Medicine (UCLA), Los Angeles. He completed his gastroenterology fellowship at UCLA also.
Dr Melmed has authored or co-authored more than 150 articles in peer-reviewed journals and several book chapters. Dr Melmed has served as Associate Editor of the American Journal of Gastroenterology, and clinical research editor for Inflammatory Bowel Disease. His interests include clinical outcomes and quality of care in inflammatory bowel disease (IBD), as well as translational prognostic and therapeutic strategies to improve inflammation and clinical outcomes. He has led or participated in the development of quality indicators for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, the National Quality Forum, and the Canadian Crohn’s and Colitis organizations.
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!